Skip to Main Content

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care (ISABELA1)

Conditions

Diseases of the Lung | Diseases of the Respiratory Systems

Phase III

What is the purpose of this trial?

Brief Summary:

The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).

  • Trial with
    GALAPAGOS NV (US)
  • Start Date
    05/29/2019
  • End Date
    12/30/2021
Trial Image

For more information about this study, contact:

Maksym Minasyan

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/01/2019
  • Study HIC
    #2000025140